Rating of Russian Pharmaceutical Distributors (Q1 – Q3 2017)
The official start of labeling of pharmaceutical drugs is surely one of the most prominent events of 2017. It is both beneficial and risky for all market players. The benefits include more product distribution control opportunities for manufacturers. The risks involve the desire of the regulators to implement the system in a very short time, which can cause a wide variety of problems for the pharmaceutical wholesalers.
Theoretically, the system will eliminate shady distributors that resell pharmaceuticals, including stolen ones, or transfer the products intended for marketing campaign to other regions. This is unlikely to cause any disturbance within the market. However, it is quite possible for the system to hit smaller regional companies that will not manage to buy the equipment, modernize the software, and raise the staff qualifications within the required time.
It can also affect pharmaceutical drug importers if the customs services become involved. Problems may arise when introducing the system to certain customs posts. At the moment, pharmaceutical drug and API imports are registered at more than 100 posts, which makes it very difficult to include them in the system synchronically.
Read more about rating of Russian pharmaceutical Distributors(Q1-Q3 2017 performance) here: http://rncph.com/news/23_08_2017
See the detailed rating in the newspaper Farmatsevtichesky Vestnik (No. 40, 12/05/2017).
Tab 1. Top 15 pharmaceutical distributors with the largest market share of direct shipments of drugs (including preferential shipments), in monetary terms (Q1 – Q3 2017)